News

Biocon arm to introduce in future three new oncology biosimilars at US healthcare conferenceBiocon Limited’s subsidiary will launch three new oncology biosimilars at a US healthcare conference, boosting its global presence and commitment to affordable cancer care. On the NSE, Biocon shares closed at ₹386.60, down ₹4.75 or 1.21% on 6 January 2026.By Srabastee Biswas  January 7, 2026, 4:35:05 PM IST (Updated)1 Min ReadBiocon Limited’s subsidiary is set to introduce three new oncology biosimilars at an upcoming healthcare conference in the United States, marking a strategic expansion of its oncology portfolio. The move is aimed at strengthening Biocon’s presence in the global biosimilars market and addressing growing demand for accessible cancer therapies.

The new oncology biosimilars are expected to complement the company’s existing pipeline, reflecting its continued focus on innovation in biologics. The announcement underscores Biocon’s commitment to advancing cancer care through affordable and high-quality treatment options, while also enhancing its global footprint.

The launch will provide insights into the company’s ongoing research, development milestones, and regulatory progress in oncology biosimilars. Market observers see this as a significant step for Biocon in consolidating its position among global biosimilars players.

Also read: Biocon employee found dead on Bengaluru campus, probe on

Investors will closely watch the rollout, as biosimilars increasingly shape treatment protocols in oncology and offer potential revenue growth.

Shares of Biocon Limited closed at ₹386.60 apiece on the NSE on January 6, 2026, down ₹4.75 or 1.21%.Continue Reading(Edited by : Shoma Bhattacharjee)First Published: Jan 6, 2026 6:52 PM ISTTagsBioconOncologyUS health regulator